Answers are grounded in this paper and cite their sources.
Observational study shows no effect of influenza vaccination on SARS-CoV-2 immunity in dialysis patients, implying vaccine benefits persist post-booster.
Annual immunisation against both COVID-19 and seasonal influenza is now becoming standard of care, particularly ahead of anticipated winter waves. These vaccines may be co-administered on the same day or sequentially on separate days. Data on immunogenicity and the impact of consecutive vaccinations on spike-specific humoral and cellular immunity in dialysis patients remain limited. In this real-world observational study, SARS-CoV-2-specific immune responses were evaluated in dialysis patients receiving the monovalent XBB.1.5 vaccine followed by a quadrivalent influenza vaccine 14 days later, or either vaccine alone. Specific antibodies and T-cells were quantified and characterized using enzyme-linked immunosorbent assay and flow-cytometry. Baseline analyses from a reference-group prior to the vaccination season showed that most patients had detectable SARS-CoV-2- and influenza-specific immunity. Both the XBB.1.5 and the influenza vaccine substantially enhanced pre-existing antigen-specific humoral and cellular responses. When comparing XBB.1.5-vaccinated patients with and without subsequent influenza-vaccination, the magnitude of XBB.1.5-induced antibody or T-cell responses did not differ. Likewise, the influenza-vaccine had no non-specific effect on SARS-CoV-2-specific immune responses. Finally, spike-specific immunity remained stable over a six-month period and persisted at levels exceeding those of unvaccinated patients assessed during the same period. In conclusion, sequential administration of COVID-19 and influenza vaccines in dialysis patients is feasible and does not compromise the immunogenicity of either vaccine. Our data are encouraging in the context of ongoing development of additional mRNA-based vaccines that may require administration in close temporal proximity to seasonal influenza immunisation, and underscore the benefit of booster vaccination in individuals with impaired immune function.
No takes yet. Share an insight, caveat, or question.
Bronder et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: